Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Licensing Agreement with Kimberly-Clark

13 Aug 2012 07:00

RNS Number : 8357J
Byotrol PLC
13 August 2012
 



 

 

 

For Immediate Release 13 August 2012

 

 

Byotrol plc Licensing Agreement with

Kimberly-Clark Corporation

 

The Board of Byotrol plc ('Byotrol' or 'the Company'), the leading AIM listed anti-microbial hygiene company is delighted to provide an update on its agreement with its Fortune 150 partner, Kimberly-Clark Corporation (Kimberly-Clark).

 

Byotrol Consumer Products (BCP), Byotrol's 50% owned consumer products subsidiary, and Kimberly-Clark have agreed to enter into a full licensing agreement (Agreement). Details of the Agreement are not being disclosed at this time.

 

The Agreement between BCP and Kimberly-Clark follows the successful completion of the initial Joint Development Agreement with a Fortune 150 partner Byotrol announced on 31 January 2012. The new, seven-year contract is global in scope, with some exceptions including certain EU markets, and provides Kimberly-Clark exclusive intellectual property rights.

 

Kimberly-Clark and its well-known global brands are an indispensable part of life for people in more than 175 countries. Every day, nearly a quarter of the world's population trust K-C's brands and the solutions they provide to enhance their health, hygiene and well-being. With brands such as Kleenex, Scott, Huggies, Pull-Ups, Kotex and Depend, Kimberly-Clark holds the No. 1 or No. 2 share position in more than 80 countries.

 

 

Commenting on the commercial agreement, Ralph Kugler, Chairman at Byotrol, said:

 

 "This is a landmark agreement for Byotrol. It realises a central tenet of our strategy by partnering with a global consumer-focussed company.

 

"We are delighted to have worked so closely with a company as respected as Kimberly-Clark in arriving at this significant result, and we appreciate the commitment to Byotrol that Kimberly-Clark has shown from the earliest stage. The agreement also reflects the outstanding effort made by our partners at BCP."

 

 

Gary Millar, Chief Executive at Byotrol, added:

 

"The successful conclusion of the initial phase of the relationship with Kimberly-Clark is a considerable endorsement of the Byotrol technology.

 

"This collaboration has been a significant step in developing Byotrol technology and we see this as a starting point to explore further potential. 

 

"Byotrol technology offers a unique advantage in the highly competitive global hygiene market. We are confident that this distinguishing quality will make Byotrol a market leader."

 

Jon Wilson, Vice President, Corporate Innovation for Kimberly-Clark, added:

 

"Delivering to market game-changing innovations is a critical element to achieving Kimberly-Clark's vision of leading the world in essentials for a better life. Key to achieving this is the creation of an innovative culture at Kimberly-Clark that fosters win-win opportunities between our organization and external partners, such as Byotrol.

 

"Innovation is a race without a finish line. We must continually incorporate new technologies, leverage fresh understandings of the consumer and find new ways to win in the marketplace. Having strategic partners, like a Byotrol, is core to Kimberly-Clark's innovation journey."

 

 

Enquiries:

 

Byotrol plc

01925 742000

Ralph Kugler, Chairman

 

Gary Millar, Chief Executive

 

Duncan Grosvenor, Finance Director

 

 

 

finnCap Limited

020 7220 0500

Nominated Adviser and broker

 

Geoff Nash/Christopher Raggett

Simon Starr (Corporate Broking)

 

 

 

Winningtons

020 3176 4722

Tom Cooper / Paul Vann

07768 807 631

 

paul.vann@winningtons.co.uk

 

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading anti-microbial technology hygiene company, operating globally in the Health, Food, Leisure, Consumer, Industrial and Agriculture sectors, providing a low toxicity product with a broad-based and long lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, microbacteria and algae.

 

The Byotrol product can be used as a stand alone product or as a complementary biocide additive to existing products to improve their performance in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Founded in 2005, the Company has prioritised the development of a technology that creates easier, safer and cleaner lives through partnering with providers of essential goods and services. Byotrol is the catalyst behind the aptly named global 'Hygiene Revolution'.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRPTMJTMBTBTJT
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.